Skip to main content

Table 5 GRADE assessments for the body of evidence for each outcome and judgment of the overall quality of evidence

From: Anti-IgE monoclonal antibody therapy for the treatment of chronic rhinosinusitis: a systematic review

Outcome

Follow-up

Risk of bias

Inconsistency

Indirectness

Imprecision

Publication bias

Overall quality of evidence

Primary outcomes

Change in CT score

       

Lund-McKay Score

16 weeks

Moderate limitation

Not relevant

No serious indirectness

Serious imprecision

Unlikely

Low

Percent opacification on CT

6 months

Moderate limitation

Not relevant

No serious indirectness

Serious imprecision

Unlikely

Low

Change in clinical polyp score

       

Total nasal endoscopic polyp score

16 weeks; 6 months

Moderate limitation

Not relevant

No serious indirectness

Serious imprecision

Unlikely

Low

Change in quality of life

       

SF-36

16 weeks

Moderate limitation

Not relevant

No serious indirectness

Serious imprecision

Unlikely

Low

AQLQ

16 weeks

Moderate limitation

Not relevant

No serious indirectness

Serious imprecision

Unlikely

Low

RSOM-31

16 weeks

Moderate limitation

Not relevant

No serious indirectness

Serious imprecision

Unlikely

Low

TNSS

6 months

Moderate limitation

Not relevant

No serious indirectness

Serious imprecision

Unlikely

Low

SNOT-20

6 months

Moderate limitation

Not relevant

No serious indirectness

Serious imprecision

Unlikely

Low

Secondary outcomes

Change in cellular inflammation

       

Eosinophil count (nasal lavage)

6 months

Moderate limitation

Not relevant

No serious indirectness

Serious imprecision

Unlikely

Low

Change in nasal airflow

       

PNIF

6 months

Moderate limitation

Not relevant

No serious indirectness

Serious imprecision

Unlikely

Low

Change in olfaction

       

UPSIT

6 months

Moderate limitation

Not relevant

No serious indirectness

Serious imprecision

Unlikely

Low

Adverse events

16 weeks; 6 months

Moderate limitation

Not relevant

No serious indirectness

Serious imprecision

Unlikely

Low

  1. SF-36 36-Item Short Form Health Survey, AQLQ Asthma Quality of Life Questionnaire, RSOM-31 Rhinosinusitis Outcome Measure 31, TNSS Total Nasal Symptom Severity, SNOT-20 Sinonasal Outcome Test 20, PNIF peak nasal inspiratory flow, UPSIT University of Pennsylvania Smell Identification Test